|
|
|
| home > ebr > Winter 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
Partnering is the lifeblood of the biotech and pharmaceutical industries and, as the industry expands, Robert Lee Kilpatrick from TVG discusses the ideal elements for successful collaborations.
|
|
|
Neil Johnson, Ad Rietveld and Chloë Brown of RJW & Partners Ltd consider the benefits of thorough in-licensing evaluation and early understanding of payers' perspectives in guaranteeing launch success.
|
|
|
|
|
Xavier Tizon at Oncodesign makes a strong case for the untapped potential of imaging biomarkers and how they can be applied in future drug development stages.
|
|
|
Simon Webster from Avacta Group PLC considers the benefits of maintaining physical stability of candidate therapeutic proteins at an early stage in the discovery process, and highlights pioneering techniques for monitoring conformational and colloidal stability.
|
|
|
|
For companies facing up to the move from proof-of-concept to proof-of-differentiation, Markus Thunecke from Catenion considers the three levels of evaluation that should be considered.
|
|
|
Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA consider if natural product programmes are ready to challenge the traditional drug cycle process.
|
|
|
By encouraging others to develop their own drugs using a patented technology, the patent owner has the potential to develop substantial revenues, observe Michael R Ward,Otis Littlefield and Anita Choi from Morrison & Foerster LLP.
|
|
|
Sekhar Medisetti at GlobalData takes a look at the niche market for Type 1 diabetes, the continuous challenge posed by patient compliance, and the problematic issue of delivery methods for insulin products.
|
|
|
|
Bill Whitford of Thermo Scientific Cell Culture and BioProcessing analyses the advantages of single-use bioreactors and the supply and performance features they offer in process development.
|
|
|
| In response to the danger posed by bacterial retention testing, Martha Folmsbee, Morven McAlister and Jerold Martin at Pall Life Sciences compare and contrast the various tests for predicting and confirming retention. |
|
|
Amin Omar at Innovotech highlights the need for finding the most suitable antimicrobial agent to avoid the potential problems of biofilm infections.
|
|
|
|
Following the launch of the Smart SME Market Validation Programme, Rebecca Philpot from the State Government of Victoria, Australia, considers other ways in which the city is changing to better accommodate the biotech industry.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Absolute Carbon Filters – Your New Way To Buy Carbon Filters
Absolute Carbon Filters Ltd. is pleased to announce that you can now buy
your carbon filters online AND have the option to deal with our
specialists directly. Absolute Carbon filters is your new manufacturer
and supplier of carbon filters in the UK, supporting all major fume
cupboard brands and filter combinations. Whatever the application, we
have the solution!
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
ASGCT 22nd Annual Meeting
29 April - 2 May 2019, Washington Hilton, Washington, D.C
The 2019 ASGCT Annual Meeting is expected to be the largest in Society
history, eclipsing the mark set by the 2018 meeting just last year. Join more
than 3,500 researchers, clinicians, advocates, and industry leaders in
discovering the latest science and technology surrounding gene and cell
therapy.
More info >> |
|
|
